15353-j-veluchamy

30 | Chapter 1 50. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy (2013) 15 (12):1563-70. Epub 2013/10/08. doi: 10.1016/j.jcyt.2013.06.017. PubMed PMID: 24094496. 51. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified donor NK- lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia (2004) 18 (11):1835-8. 52. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klinische Padiatrie (2005) 217 (6):345-50. Epub 2005/11/25. doi: 10.1055/s-2005-872520. PubMed PMID: 16307421. 53. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. British journal of haematology (2008) 143 (5):641- 53. doi: 10.1111/j.1365-2141.2008.07340.x. PubMed PMID: PMC3602915. 54. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee J-H, Lee J-H, et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant (2010) 45 (6):1038-46. doi: http:// www.nature.com/bmt/journal/v45/n6/suppinfo/bmt2009304s1.html. 55. Rizzieri DA, Storms R, Chen D-F, Long G, Yang Y, Nikcevich DA, et al. NATURAL KILLER CELL ENRICHED DONOR LYMPHOCYTE INFUSIONS FROM A 3-6/6 HLA MATCHED FAMILY MEMBER FOLLOWING NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2010) 16 (8):1107-14. doi: 10.1016/j.bbmt.2010.02.018. PubMed PMID: PMC3625653. 56. Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess S, et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One (2011) 6 (11):e27351. Epub 2011/11/19. doi: 10.1371/ journal.pone.0027351. PubMed PMID: 22096557; PubMed Central PMCID: PMCPMC3212563. 57. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105 . doi: 10.1182/blood-2004-07-2974. 58. Copelan EA. Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine (2006) 354 (17):1813-26. doi: doi:10.1056/NEJMra052638. PubMed PMID: 16641398. 59. Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol (2017) 8 :631. Epub 2017/06/18. doi: 10.3389/fimmu.2017.00631. PubMed PMID: 28620386; PubMed Central PMCID: PMCPMC5450018. 60. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non- small cell lung cancer. Cancer Immunology, Immunotherapy (2010) 59 (12):1781-9. doi: 10.1007/ s00262-010-0904-3.